The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience

BACKGROUND: Genomic tests are increasingly being used by clinicians when considering adjuvant chemotherapy for patients with oestrogen receptor-positive (ER+), human epidermal growth factor 2-negative (HER2−) breast cancer. The Oncotype DX breast recurrence score assay was the first test available i...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Breast Cancer Res Treat
Autors principals: Crolley, Valerie E., Marashi, Husam, Rawther, Shabbir, Sirohi, Bhawna, Parton, Marina, Graham, Janine, Vinayan, Anup, Sutherland, Stephanie, Rigg, Anne, Wadhawan, Anshu, Harper-Wynne, Catherine, Spurrell, Emma, Bond, Hannah, Raja, Fharat, King, Judy
Format: Artigo
Idioma:Inglês
Publicat: Springer US 2020
Matèries:
Epidemiology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7103011/
https://ncbi.nlm.nih.gov/pubmed/32170635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-020-05578-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars